Delcath Systems (DCTH) Scheduled to Post Earnings on Monday

Delcath Systems (NASDAQ:DCTH) is set to post its quarterly earnings results after the market closes on Monday, August 5th. Analysts expect Delcath Systems to post earnings of ($0.34) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Delcath Systems (NASDAQ:DCTH) last issued its earnings results on Tuesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.43). The company had revenue of $3.14 million during the quarter, compared to analyst estimates of $3.70 million. Delcath Systems had a negative return on equity of 290.07% and a negative net margin of 1,080.72%. On average, analysts expect Delcath Systems to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Delcath Systems Price Performance

Shares of DCTH stock opened at $8.12 on Friday. The firm has a market capitalization of $225.62 million, a price-to-earnings ratio of -3.06 and a beta of 0.64. The business has a fifty day moving average of $7.80 and a 200 day moving average of $5.94. Delcath Systems has a 1 year low of $2.25 and a 1 year high of $9.18.

Analyst Upgrades and Downgrades

DCTH has been the subject of a number of research analyst reports. Stephens initiated coverage on Delcath Systems in a research note on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 target price for the company. HC Wainwright raised their target price on Delcath Systems from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, May 15th. Finally, Craig Hallum assumed coverage on Delcath Systems in a research note on Friday, June 28th. They set a “buy” rating and a $18.00 price objective for the company. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Delcath Systems presently has a consensus rating of “Moderate Buy” and an average price target of $19.83.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.